Method for directed catalytic functionalization of alcohols
10005719 ยท 2018-06-26
Assignee
Inventors
Cpc classification
C07C67/347
CHEMISTRY; METALLURGY
C07C67/31
CHEMISTRY; METALLURGY
C07C231/12
CHEMISTRY; METALLURGY
C07C29/44
CHEMISTRY; METALLURGY
C07C67/31
CHEMISTRY; METALLURGY
C07D491/048
CHEMISTRY; METALLURGY
International classification
C07C231/12
CHEMISTRY; METALLURGY
C07C29/44
CHEMISTRY; METALLURGY
C07D491/048
CHEMISTRY; METALLURGY
Abstract
A method of preparing ortho-alkenyl and ortho-acetyl benzylic alcohols is disclosed.
Claims
1. A method for the ortho-arylation of a benzylic alcohol, comprising the steps of: (a) generating a quinolinyl hemiacetal benzoate scaffold having the formula II; ##STR00015## (b) reacting a benzylic alcohol of formula I ##STR00016## with the quinolinyl hemiacetal benzoate scaffold of formula II in the presence of trifluoroacetic acid to provide a compound of formula III: ##STR00017## (c) reacting the compound of formula III with an arylboronic pinacol ester having the formula IVa: ##STR00018## in the presence of a palladium acetate, rhodium acetate, or ruthenium acetate catalyst; an N-acetylated amino acid metal catalyst ligand selected from the group consisting of Ac-Glycine-OH, Ac-Valine-OH, Ac-Alanine-OH, Ac-Leucine-OH, Ac-Isoleucine-OH, and Ac-tert-butylleucine-OH; a silver salt; and a base selected from the group consisting of: Na.sub.2CO.sub.3, KHCO.sub.3, K.sub.2CO.sub.3, K.sub.3PO.sub.4, and Cs.sub.2CO.sub.3 to provide a compound of formula Va: ##STR00019## (d) reacting the compound formula Va of step (c) with an acid and an alcohol, said alcohol having the formula R.sub.13OH to provide an ortho-arylated benzylic alcohol of formula VIa ##STR00020## and a quinolinyl hemiacetal alkoxy scaffold having the formula VII; ##STR00021## wherein R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of: hydrogen, an alkyl, an aryl, R.sub.1 and R.sub.2 forming an aryl ring, and R.sub.2 and R.sub.3 forming an aryl ring; R.sub.11 and R.sub.12 are independently hydrogen or an alkyl; and R.sub.13 is an alkyl or substituted alkyl; Ar is an unsubstituted or substituted aryl; and n is 1 or 2.
2. The method of claim 1 wherein, when R.sub.1 and R.sub.2 of the benzylic alcohol having the formula I are both hydrogen, the compound having formula VIa is diarylated and R.sub.1 of the compound VIa is an aryl.
3. The method of claim 1, further comprising repeating steps (b)-(d), wherein the quinolinyl hemiacetal alkoxy scaffold VII released in step (d) reacts with the benzylic alcohol I in step (b) to further generate compound III.
4. The method of claim 1, wherein the method further comprises the step of isolating the ortho-arylated benzylic alcohol of formula VIa.
5. The method of claim 1, wherein the catalyst is palladium acetate (Pd(OAc).sub.2).
6. The method of claim 1, wherein the N-acetylated amino acid metal catalyst ligand is Ac-Isoleucine-OH.
7. The method of claim 1, wherein the silver salt is silver carbonate Ag.sub.2CO.sub.3.
8. The method of claim 1, wherein the base is K.sub.2CO.sub.3.
9. The method of claim 1, wherein the Ar is an aryl group having at least one substituent group, wherein each at least one substituent group is independently selected from the group consisting of an alkyl, an alkoxy, an halogenated alkyl, and an alkoxycarbonyl.
10. The method of claim 9, wherein the aryl group has at least one substituent group, wherein each substituent is an alkyl.
11. The method of claim 10, wherein the aryl group has at least one substituent group, wherein each substituent is a methyl.
12. The method of claim 1, wherein step (c) is in the presence of palladium acetate (Pd(OAc).sub.2), Ac-Isoleucine-OH, silver carbonate (Ag.sub.2CO.sub.3), and K.sub.2CO.sub.3.
Description
BRIEF DESCRIPTION OF THE FIGURES
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
DETAILED DESCRIPTION
(11) Aspects, features and advantages of several exemplary embodiments of the present invention will become better understood with regard to the following description in connection with the accompanying drawing(s). It should be apparent to those skilled in the art that the described embodiments of the present invention provided herein are illustrative only and not limiting, having been presented by way of example only. All features disclosed in this description may be replaced by alternative features serving the same or similar purpose, unless expressly stated otherwise. Therefore, numerous other embodiments of the modifications thereof are contemplated as falling within the scope of the present invention as defined herein and equivalents thereto. Hence, use of absolute terms such as, for example, will, will not, shall, shall not, must and must not are not meant to limit the scope of the present invention as the embodiments disclosed herein are merely exemplary.
(12) The word exemplary is used herein to mean serving as an example, instance, or illustration. Any aspect described herein as exemplary is not necessarily to be construed as exclusive, preferred or advantageous over other aspects.
(13) Alkyl means C.sub.1-C.sub.12 alkyl, optionally substituted by one or more halogen; or alkyl means C.sub.1-C.sub.6 alkyl, optionally substituted by one or more halogen; or alkyl means C.sub.1-C.sub.3 alkyl, optionally substituted by one or more halogen.
(14) Alkyl may be methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, each independently and optionally substituted by one or more halogen.
(15) R.sub.11 and R.sub.12 may both be hydrogen; or R.sub.11 is methyl and R.sub.12 is hydrogen; R.sub.11 and R.sub.12 may both be methyl.
(16) Aryl or Ar means a carbocyclic or heterocyclic aromatic ring that is optionally substituted or fused with another ring.
(17) Ar in the compounds of formula IVa, Va, and VIa may be substituted by one or more alkyl, O-alkyl, COOalkyl, and/or haloalkyl.
(18) In scheme 7 and 7a, the starting benzyl alcohols may be substituted ortho to the benzylic alcohol by haloalkyl, O-alkyl, nitro, or aryl.
(19) PyA and QuA are defined in Scheme 5.
(20) Halogen means fluorine, chlorine, bromine or iodine.
(21) Transition metal means Paladium, Rhodium, or Ruthenium. Transition metal catalysts include Pd(OAc).sub.2 or a Rhodium acetate, or salt thereof, or a Ruthenium acetate, or a salt thereof. The amount of the transition metal catalyst may be from about 5 mol % to about 50 mol %, or from about 10 mol % to about 40 mol %, or from about 10 mol % to about 40 mol %, or from about 10 mol % to about 30 mol %.
(22) In an embodiment, the process may further comprise a metal catalyst ligand. The ligand may be carboxylic acid, a peptide, e.g., a dipeptide or tripeptide with a carboxylic acid functional group. Examples of a ligand include N-acetyl-isoLeucine (Ac-Ile-OH, CAS Reg. No. 3077-46-1); N-acetyl-tert-butylleucine (Ac-tert-Leu-OH); and N-acetyl glycine (Ac-Gly-OH, CAS Reg, No. 543-24-8). The amount of the ligand may be from about 5 mol % to about 50 mol %, or from about 10 mol % to about 40 mol %, or from about 20 mol % to about 40 mol %, or from about 20 mol % to about 30 mol %.
(23) In an embodiment, the process may further comprise a silver salt, e.g., silver carbonate. The amount of the silver salt may be from about 0.1 to about 5 equivalents, or from about 0.5 to about 4 equivalents, or from about 1 to about 4 equivalents. The process comprising the transition metal may be effected in a fluorinated solvent, e.g., 1,1,1,3,3,3-hexafluoro-2-propanol. The process may be effected at a temperature of from ambient temperature, to about the boiling point of the solvent.
(24) The term rsm means recovered starting material.
EXAMPLES
Example 1
(25) Synthesis of Molecular Scaffold of Formula 18:
(26) As shown in Scheme 1 (
Example 2
(27) Use of Molecular Scaffold 18 to Functionalize Benzylic Alcohols:
(28) As shown in Scheme 2 (
(29) In another embodiment, as shown in Scheme 3 (
(30) In another embodiment, the scaffold compound 2 may be recovered. Benzylic alcohol 9 was coupled with alkene 18 in the presence of Pd(OAc).sub.2 to provide compound 19. Compound 19 was treated with gaseous hydrogen chloride in methanol to yield alcohol 20 and compound 2 in high yields.
Example 3
(31) Reaction of Phenyl-BPin (Table 1):
(32) Reaction of one equivalent of 2-methylbenzylOPyA with PhBPin (3 equiv) under the catalysis of Pd(OAc).sub.2 (10 mol %) and Ac-Gly-OH (20 mol %), Ag.sub.2CO.sub.3 (1 equiv) and CsF (2 equiv) as the additives in HFIP (0.1 M) at 90 C. for 6 h, the desired product was afforded in 11% NMR yield, with 83% NMR yield of rsm (entry 1, Table 1).
(33) TABLE-US-00001 TABLE 1
(34) Then Na.sub.2CO.sub.3 (2 equiv) gave the best result (34/3% mono/di, 51% rsm, entry 8, Table 1) among different bases. Reagent ratio and concentration shows that more oxidants (2 equiv), less base (1 equiv), and less concentration (0.05 M) gave a better result (43/4% mono/di, 38% rsm, entries 9-15, Table 1).
(35) Other embodiments are provided in the examples of Schemes 4 and 6a (
Example 4
(36) The residue QuA was prepared and attached to 2-methyl benzyl alcohol according to Scheme 7 (
Example 5
(37) When the QuA-attached benzyl alcohol was subjected to the coupling reaction (see substantially same conditions of Example 3), higher yield (69% NMR yield of mono) was achieved (entry 1, Table 2).
(38) TABLE-US-00002 TABLE 2.sup.a
(39) Interestingly, a second arylation of the new formed phenyl group could be afforded in 8% NMR yield, plus 17% rsm. After screening of different bases, K.sub.2CO.sub.3 (2 equiv) gave the best yield (75/14% mono/di, 6% rsm, entry 4, Table 2). Less amount of Pd(OAc).sub.2 (5 mol %) or lower temperature both led to decreased yields even with longer reaction time (entry 7, 9, Table 2). PhBF.sub.3K showed lower reactivity than PhBPin (entry 10, Table 1). Benzoquinone and water, which were supposed to increase the reduction elimination rates, did not show any advantages in this chemistry (entry 11, 12, Table 2).
(40) In studies on the effects of the ligands, Ac-Ile-OH turned out to be the best one (with a much better mono/di ratio, entry 16, Table 2). Ac-tert-Leu-OH gave the best mono/di ratio, but lower yield (entry 17, Table 2). Apparently bulky ligand can control the form of the di-product, but lead to a lower yield. Finally we chose entry 16 in Table 2 as the optimized conditions for further studies.
(41) With reference to Schemes 7a and 7b (
(42) With reference to Scheme 8 (
(43) Therefore, although selected aspects have been illustrated and described in detail, it will be understood that various substitutions and alterations may be made therein without departing from the spirit and scope of the present invention, as defined by the following claims.